Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical evidence of pharmacokinetic changes in thalidomide therapy.

Nakamura K, Matsuzawa N, Ohmori S, Ando Y, Yamazaki H, Matsunaga T.

Drug Metab Pharmacokinet. 2013;28(1):38-43. Epub 2012 Nov 20. Review.

2.

Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients.

Matsuzawa N, Nakamura K, Matsuda M, Ishida F, Ohmori S.

Biol Pharm Bull. 2012;35(3):317-20.

3.

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.

Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB.

BMC Cancer. 2010 Aug 4;10:404. doi: 10.1186/1471-2407-10-404.

4.

Thalidomide for erythema nodosum leprosum and other applications.

Okafor MC.

Pharmacotherapy. 2003 Apr;23(4):481-93. Review.

PMID:
12680478
6.

Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

Clarke JD, Cherrington NJ.

Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):349-60. doi: 10.1517/17425255.2012.656087. Epub 2012 Jan 27. Review.

7.

The role of thalidomide in the management of erythema nodosum leprosum.

Walker SL, Waters MF, Lockwood DN.

Lepr Rev. 2007 Sep;78(3):197-215. Review.

PMID:
18035771
8.

Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.

Egger T, Dormann H, Ahne G, Pahl A, Runge U, Azaz-Livshits T, Neubert A, Criegee-Rieck M, Gassmann KG, Brune K.

Drugs Aging. 2005;22(3):265-72.

PMID:
15813658
9.

Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.

Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, Acharya M, Chan K, Cohen N, Dudov A.

Clin Pharmacokinet. 2009;48(3):199-209. doi: 10.2165/00003088-200948030-00006.

PMID:
19385713
10.

Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity.

Kumar N, Sharma U, Singh C, Singh B.

Curr Top Med Chem. 2012;12(13):1436-55. Review.

PMID:
22650376
11.

Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma.

Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, Chen Y, Zhou L.

Haematologica. 2007 Sep;92(9):1246-9. Epub 2007 Aug 1.

12.

Clinical pharmacology of thalidomide.

Eriksson T, Björkman S, Höglund P.

Eur J Clin Pharmacol. 2001 Aug;57(5):365-76. Review.

PMID:
11599654
13.

Thalidomide: a re-look.

Grover JK, Vats V, Gopalakrishna R, Ramam M.

Natl Med J India. 2000 May-Jun;13(3):132-41. Review.

PMID:
11558112
14.

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.

Breitkreutz I, Anderson KC.

Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):973-85. doi: 10.1517/17425255.4.7.973 . Review.

PMID:
18624684
15.

Theoretical basis for the activity of thalidomide.

Meierhofer C, Dunzendorfer S, Wiedermann CJ.

BioDrugs. 2001;15(10):681-703. Review.

PMID:
11604049
16.

Clinical pharmacokinetics of thalidomide.

Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL.

Clin Pharmacokinet. 2004;43(5):311-27. Review.

PMID:
15080764
17.

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

de Leon J, Susce MT, Murray-Carmichael E.

Mol Diagn Ther. 2006;10(3):135-51. Review.

PMID:
16771600
18.

[Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum].

Ishii N, Ishida Y, Okano Y, Ozaki M, Gidoh M, Kumano K, Goto M, Nogami R, Hatano K, Yamada A, Yotsu RR.

Nihon Hansenbyo Gakkai Zasshi. 2011 Sep;80(3):275-85. Review. Japanese.

PMID:
21941834
19.

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.

Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD.

Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.

PMID:
12642692
20.

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.

Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL.

J Am Acad Dermatol. 1996 Dec;35(6):969-79. Review.

PMID:
8959957

Supplemental Content

Support Center